Table 2.
General characteristics of controls and patients on HD and PD
| Characteristics | Control (N=15) | HD (N=25) | PD (N=20) |
|---|---|---|---|
| General characteristics | |||
| Age, yr | 46 (36–58) | 56 (43–73) | 67 (56–84)a,b |
| Gender, % male | 56 | 43 | 56 |
| BMI, kg/m2 | 26 (24–28) | 24 (20–26) | 25 (23–28) |
| Comorbidities | |||
| HT, n (%) | 3 (21) | 17 (74) | 19 (95) |
| Stroke, n (%) | 0 (0) | 2 (9) | 1 (5) |
| CHD, n (%) | 0 (0) | 5 (22) | 3 (15) |
| Cardiopathy, n (%) | 0 | 9 (39) | 8 (40) |
| PVD, n (%) | 0 | 4 (17) | 3 (15) |
| Therapies, n | |||
| Statins | 0 | 6 | 5 |
| PI | 0 | 5 | 6 |
| RASi | 1 | 3 | 11 |
| β-Blockers | 1 | 5 | 4 |
| CCB | 1 | 1 | 6 |
| Biologic parameters | |||
| Urea, mmol/L | 5.4 (4.4–7.5) | 17.1 (13.3–19.8)a | 18.8 (16.1–22.6)a |
| Creatinine, µmol/L | 73 (69–85) | 702 (506–862)a | 575 (422–758)a |
| mGFR, ml/min per 1.73 m2 | 94 (86–96) | — | — |
| Total cholesterol, mg/dl | 208 (189–237) | 149 (113–180)a | 209 (155–232)b |
| LDL cholesterol, mg/dl | 139 (105–158) | 71 (54–103)a | 125 (81–159)b |
| HDL cholesterol, mg/dl | 59 (53–66) | 41 (30–47)a | 45 (36–62)a |
| Triacylglycerols, mg/dl | 91 (64–116) | 119 (88–173)a | 149 (118–207)a |
| CRP, mg/L | 1.9 (0.5–3.5) | 3.3 (1.9–8.0) | 3.7 (1.7–5.8) |
Data are expressed as median (interquartile range). eGFR measured by the CKD Epidemiology Collaboration formula. BMI, body mass index; HT, hypertension; CHD, coronary heart disease; PVD, peripheral vascular disease; PI, platelet inhibitor; RASi, renin-angiotensin system inhibitor; CCB, calcium-channel blocker; mGFR, measured GFR by iohexol clearance; CRP, C-reactive protein.
a
P<0.05 versus controls.
b
P<0.05 versus HD, Mann–Whitney U test.